Immunotherapy Agent Can Reduce Viral Levels in SIV-Infected Monkeys

by Shirley Johanna on  February 26, 2016 at 6:50 PM Research News   - G J E 4
Immunotherapy can push SIV (simian immunodeficiency virus) out of its hiding place in infected monkeys that have the virus controlled with drugs, say scientists at Yerkes National Primate Research Center, Emory University report.
Immunotherapy Agent Can Reduce Viral Levels in SIV-Infected Monkeys
Immunotherapy Agent Can Reduce Viral Levels in SIV-Infected Monkeys

The results were presented on February 24 at the Conference on Retroviruses and Opportunistic Infections in Boston by graduate student Geetha Mylvaganam.

‘Simian immunodeficiency viruses (SIVs) are retroviruses that infect non-human primates, which includes apes, monkeys and chimpanzees.’
Rama Rao Amara, PhD, professor of microbiology and immunology at Yerkes and the Emory Vaccine Center, led the project. Collaborators include Rafi Ahmed, PhD, director of Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar, and Gordon Freeman, PhD, of Dana-Farber Cancer Institute. Mylvaganam is part of the Immunology and Molecular Pathogenesis graduate program at Emory.

Antiretroviral drugs can usually control HIV in chronically infected people, but they can't completely eliminate it. That's because some immune cells harboring the virus remain dormant. A strategy has emerged called "shock and kill" or "kick and kill", aimed at activating those cells, so that the virus can be flushed out.

The Yerkes team tested the effects of blocking PD-1, a molecule that inhibits the immune response during chronic infections, in combination with antiretroviral therapy. Antibodies that block PD-1 have also been tested, with some success, as cancer immunotherapy agents. The team developed a "primatized" anti-PD-1 antibody, to reduce monkeys' immune responses to the antibody itself and enable repeated infusions.

With some SIV-infected monkeys, the researchers treated them with anti-PD-1 antibody for 14 days, starting from 10 days before antiretroviral therapy began. In this situation, the anti-PD-1-treated animals showed more rapid viral suppression (average 42 days in the PD-1 group versus 140 days in controls) and more active antiviral T cells.

In addition, other SIV-infected monkeys were treated with anti-PD-1 antibody (three infusions, with a month between each) after antiretroviral therapy had brought viral levels to a very low level. This resulted in transient reappearances of SIV in their blood, not seen in control animals.

The researchers conclude, "These results reveal for the first time the potential of PD-1 blockade, both on restoring anti-viral CD8 T cell function, and possibly destabilizing the viral reservoir under ART. They highlight the potential of PD-1 blockade to work synergistically with other therapeutic agents such as vaccines and latency reversing agents to effectively diminish HIV reservoir under ART as a means to establish a functional cure."

Source: Eurekalert

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All